Study on Darovasertib and Crizotinib for Treating Non-Metastatic Uveal Melanoma

Inclusion Criteria

• Diagnosed with primary uveal melanoma at high risk of coming back (Stage II or III).
• Completed initial treatment like surgery or radiation.
• In good general health with an ECOG performance status of 0 or 1.
• Have good organ function.
• Aged 18 or older.
• Able to understand and sign a consent form.
• Completed initial treatment within 120 days before starting the study.
• Agree to use contraception if applicable.

Exclusion Criteria

• Have had previous systemic treatment for uveal melanoma.
• Show signs of cancer spread.
• Have another active cancer, except for certain skin cancers or other non-threatening cancers.
• Have AIDS-related illness.
• Have lung diseases like interstitial lung disease or pneumonitis.
• Have a history of fainting, which will be reviewed individually.
• Have active hepatitis B or C.
• Have digestive issues that affect medication absorption.
• Are pregnant or breastfeeding.
• Have heart problems.
• Had a stroke in the last 6 months.
• Are taking medications that interfere with the study drugs.
• Have allergies to certain meat products or gelatin.